A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD
NCT ID: NCT00163098
Last Updated: 2006-10-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
136 participants
INTERVENTIONAL
2004-12-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UK-369,003
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 10 pack year history of smoking
Exclusion Criteria
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Córdoba, Córdoba Province, Argentina
Pfizer Investigational Site
San Miguel de Tucumán, Pcia de Tucuman, Argentina
Pfizer Investigational Site
San Miguel de Tucumán, Pcia de Tucuman, Argentina
Pfizer Investigational Site
Rosario, Santa Fé, Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Ciudad de Beurnos Aires, , Argentina
Pfizer Investigational Site
Ciudad de Buenos Aires,, , Argentina
Pfizer Investigational Site
Ciudad de Buenos Aires, , Argentina
Pfizer Investigational Site
Ciudad de Buenos Aires, , Argentina
Pfizer Investigational Site
Provincia de Buenos Aires, , Argentina
Pfizer Investigational Site
Camperdown, New South Wales, Australia
Pfizer Investigational Site
Darlinghurst, New South Wales, Australia
Pfizer Investigational Site
Chermside, Queensland, Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia
Pfizer Investigational Site
Melbourne, Victoria, Australia
Pfizer Investigational Site
Perth, Western Australia, Australia
Pfizer Investigational Site
Giessen, , Germany
Pfizer Investigational Site
Greifestein, , Germany
Pfizer Investigational Site
Kochi, Kerala, India
Pfizer Investigational Site
Mumbai, Maharashtra, India
Pfizer Investigational Site
Pune, Maharashtra, India
Pfizer Investigational Site
Chennai, Tamil Nadu, India
Pfizer Investigational Site
Vellore, Tamil Nadu, India
Pfizer Investigational Site
Papworth Everard, Cambridgeshire, United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Newcastle upon Tyne, , United Kingdom
Pfizer Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3711028
Identifier Type: -
Identifier Source: org_study_id